484 related articles for article (PubMed ID: 34647354)
1. Psoriasiform dermatitis during dupilumab treatment for moderate-to-severe atopic dermatitis in children.
Parker JJ; Sugarman JL; Silverberg NB; Gonzalez ME; Ramien ML; Teng JMC; Paller AS
Pediatr Dermatol; 2021 Nov; 38(6):1500-1505. PubMed ID: 34647354
[TBL] [Abstract][Full Text] [Related]
2. Case report: Clinical and histopathological characteristics of psoriasiform erythema and
Ali K; Wu L; Qiu Y; Li M
Front Med (Lausanne); 2022; 9():932766. PubMed ID: 35966849
[TBL] [Abstract][Full Text] [Related]
3. A pediatric case of dupilumab-induced pustular psoriasis.
Dang N; Zheng H; Ren Y
J Dermatolog Treat; 2024 Dec; 35(1):2333016. PubMed ID: 38839072
[TBL] [Abstract][Full Text] [Related]
4. Dupilumab-Associated Psoriasis and Psoriasiform Manifestations: A Scoping Review.
Su Z; Zeng YP
Dermatology; 2023; 239(4):646-657. PubMed ID: 37100035
[TBL] [Abstract][Full Text] [Related]
5. Dupilumab-induced psoriasiform dermatitis in two pediatric cardiac transplant patients.
Lockard T; Mullen SA; Lee EB; Niebur H; Harter N
Pediatr Dermatol; 2024; 41(3):508-511. PubMed ID: 38097389
[TBL] [Abstract][Full Text] [Related]
6. Dupilumab-associated psoriasis and psoriasiform dermatitis in patients with atopic dermatitis.
Casale F; Nguyen C; Dobry A; Smith J; Mesinkovska NA
Australas J Dermatol; 2022 Aug; 63(3):394-397. PubMed ID: 35460570
[No Abstract] [Full Text] [Related]
7. Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical trial (LIBERTY AD CAFÉ).
de Bruin-Weller M; Thaçi D; Smith CH; Reich K; Cork MJ; Radin A; Zhang Q; Akinlade B; Gadkari A; Eckert L; Hultsch T; Chen Z; Pirozzi G; Graham NMH; Shumel B
Br J Dermatol; 2018 May; 178(5):1083-1101. PubMed ID: 29193016
[TBL] [Abstract][Full Text] [Related]
8. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial.
Blauvelt A; de Bruin-Weller M; Gooderham M; Cather JC; Weisman J; Pariser D; Simpson EL; Papp KA; Hong HC; Rubel D; Foley P; Prens E; Griffiths CEM; Etoh T; Pinto PH; Pujol RM; Szepietowski JC; Ettler K; Kemény L; Zhu X; Akinlade B; Hultsch T; Mastey V; Gadkari A; Eckert L; Amin N; Graham NMH; Pirozzi G; Stahl N; Yancopoulos GD; Shumel B
Lancet; 2017 Jun; 389(10086):2287-2303. PubMed ID: 28478972
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness of dupilumab in pediatric patients with a nummular phenotype of atopic dermatitis.
Kim EJ; Hlobik M; Ho T
Pediatr Dermatol; 2024; 41(3):455-457. PubMed ID: 38303143
[TBL] [Abstract][Full Text] [Related]
10. Dupilumab-induced skin-associated side effects in patients with chronic rhinosinusitis with nasal polyposis.
Chromy D; Bartosik T; Brkic FF; Quint T; Tu A; Eckl-Dorna J; Schneider S; Bangert C
J Dermatol; 2023 Jan; 50(1):89-93. PubMed ID: 36177732
[TBL] [Abstract][Full Text] [Related]
11. Pustular Psoriasis Appearing Induced by Dupilumab Therapy in a Patient With Atopic Dermatitis.
Jia X; Li C; Wu J; Liu Q
J Drugs Dermatol; 2022 Mar; 21(3):311-312. PubMed ID: 35254760
[TBL] [Abstract][Full Text] [Related]
12. Dupilumab for children and adolescents with atopic dermatitis: An Asian perspective.
Chia SY; Wee LWY; Koh MJA
Dermatol Ther; 2021 May; 34(3):e14933. PubMed ID: 33751751
[TBL] [Abstract][Full Text] [Related]
13. Weight gain in patients with severe atopic dermatitis treated with dupilumab: a cohort study.
Johansson EK; Ivert LU; Bradley B; Lundqvist M; Bradley M
BMC Dermatol; 2020 Sep; 20(1):8. PubMed ID: 32962676
[TBL] [Abstract][Full Text] [Related]
14. New-onset head and neck dermatitis in adolescent patients after dupilumab therapy for atopic dermatitis.
Bax CE; Khurana MC; Treat JR; Castelo-Soccio L; Rubin AI; McMahon PJ
Pediatr Dermatol; 2021 Mar; 38(2):390-394. PubMed ID: 33426747
[TBL] [Abstract][Full Text] [Related]
15. Off-label use of dupilumab for pediatric patients with atopic dermatitis: A multicenter retrospective review.
Igelman S; Kurta AO; Sheikh U; McWilliams A; Armbrecht E; Jackson Cullison SR; Kress DW; Smith A; Castelo-Soccio L; Treat J; Boothe WD; Diaz LZ; Levy ML; Patel A; Lee LW; Fraile-Alonso MC; Antaya RJ; Shah S; Kittler N; Arkin L; Siegfried E
J Am Acad Dermatol; 2020 Feb; 82(2):407-411. PubMed ID: 31606479
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of adult patients with atopic dermatitis treated with dupilumab: A single-center real-life experience.
Su Küçük Ö; Güneş B; Taşlidere N; Işik BG; Akaslan TÇ; Özgen FP; Bahali AG
J Cosmet Dermatol; 2022 Oct; 21(10):4781-4787. PubMed ID: 35038377
[TBL] [Abstract][Full Text] [Related]
17. Economic Evaluation of Dupilumab for Moderate-to-Severe Atopic Dermatitis: A Cost-Utility Analysis.
Zimmermann M; Rind D; Chapman R; Kumar V; Kahn S; Carlson J
J Drugs Dermatol; 2018 Jul; 17(7):750-756. PubMed ID: 30005097
[TBL] [Abstract][Full Text] [Related]
18. Dupilumab for the Treatment of Atopic Dermatitis.
Ferreira S; Torres T
Actas Dermosifiliogr (Engl Ed); 2018 Apr; 109(3):230-240. PubMed ID: 29422431
[TBL] [Abstract][Full Text] [Related]
19. Long-term effectiveness and safety of treatment with dupilumab in patients with atopic dermatitis: Results of the TREAT NL (TREatment of ATopic eczema, the Netherlands) registry.
Bosma AL; de Wijs LEM; Hof MH; van Nieuwenhuizen BR; Gerbens LAA; Middelkamp-Hup MA; Hijnen D; Spuls PI
J Am Acad Dermatol; 2020 Nov; 83(5):1375-1384. PubMed ID: 32485210
[TBL] [Abstract][Full Text] [Related]
20. Superimposed linear atopic dermatitis treated with dupilumab.
Leszczynska MA; Trainor MA; Henkel E; Keeling BH; Diaz LZ
Pediatr Dermatol; 2021 Sep; 38(5):1377-1378. PubMed ID: 34272754
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
